Empirical Asset Management LLC Has $1.02 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Empirical Asset Management LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 25.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,170 shares of the biopharmaceutical company’s stock after acquiring an additional 1,882 shares during the quarter. Empirical Asset Management LLC’s holdings in Gilead Sciences were worth $1,017,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Brighton Jones LLC lifted its stake in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 2,450 shares during the period. Bison Wealth LLC acquired a new position in Gilead Sciences in the fourth quarter valued at about $215,000. GAMMA Investing LLC lifted its stake in Gilead Sciences by 24.9% in the first quarter. GAMMA Investing LLC now owns 22,760 shares of the biopharmaceutical company’s stock valued at $2,550,000 after buying an additional 4,532 shares during the period. Wealth Enhancement Advisory Services LLC lifted its stake in Gilead Sciences by 4.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 292,966 shares of the biopharmaceutical company’s stock valued at $32,827,000 after buying an additional 13,194 shares during the period. Finally, Sowell Financial Services LLC acquired a new position in Gilead Sciences in the first quarter valued at about $912,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Down 0.4%

NASDAQ GILD opened at $117.85 on Friday. The firm has a market cap of $146.23 billion, a P/E ratio of 23.48, a P/E/G ratio of 0.81 and a beta of 0.34. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The stock’s 50-day moving average is $115.15 and its 200-day moving average is $110.45. Gilead Sciences, Inc. has a one year low of $85.60 and a one year high of $121.83.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s revenue was up 1.4% compared to the same quarter last year. During the same quarter last year, the firm posted $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were issued a dividend of $0.79 per share. The ex-dividend date was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio (DPR) is presently 62.95%.

Analysts Set New Price Targets

Several equities analysts have weighed in on GILD shares. Daiwa America raised Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 19th. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $135.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, September 16th. Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price on the stock in a research note on Friday, July 25th. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target on the stock in a research report on Tuesday, August 19th. Finally, Royal Bank Of Canada raised their price target on Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $118.65.

Insider Buying and Selling

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Thursday, August 28th. The stock was sold at an average price of $113.63, for a total transaction of $1,136,300.00. Following the completion of the transaction, the chief executive officer directly owned 595,725 shares in the company, valued at approximately $67,692,231.75. This trade represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the transaction, the insider owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 69,000 shares of company stock worth $7,986,340. 0.27% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.